 5. Subject has received radiotherapy 4 weeks or limited field radiation for palliation 2 weeks prior to starting investigational product IP, andor from whom 30 of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed. 